GMAB

Genmab

• Benzinga·1d ago

  Corbus Offers Upside Despite Post-FDA Update, Analyst Highlights Competitive Edge

• Reuters·1d ago

  Genmab publishes presentation for March 19 annual general meeting in Copenhagen

• Seeking Alpha·4d ago

  Johnson & Johnson: Success In Multiple Myeloma Underpins $25B In Growth By 2030

• TipRanks·6d ago

  Wells Fargo Sticks to Its Buy Rating for Genmab (GMAB)

• TipRanks·04/01 20:24

  Genmab Discloses April 1 Vesting of Restricted Stock Units by Top Executives

• TipRanks·04/01 20:02

  Genmab Discloses Orbis as New 5% Major Shareholder

• Reuters·04/01 07:24

  Orbis Investment Management reports 5.01% stake in Genmab

• Reuters·04/01 05:07

  Genmab names Margarida Duarte general manager for Europe and emerging markets

• Seeking Alpha·03/31 19:34

  Bicara: Maintaining 'Buy' Rating On Ficerafusp Alfa Phase 3 Advancement

• Benzinga·03/31 14:51

  FDA Adverse Event Monitoring System Q4 2025 Flags Multiple Potential New Drug Safety Signals, Including Hypersensitivity, Hypogammaglobulinemia, Colitis, Aplastic Anemia And Rhabdomyolysis Under Evaluation

• TipRanks·03/30 22:40

  Genmab Discloses Orbis as 4.99% Major Shareholder

• Reuters·03/30 16:01

  Orbis Investment cuts Genmab stake to 4.99% voting rights

• TipRanks·03/27 13:51

  Wix downgraded, TripAdvisor upgraded: Wall Street’s top analyst calls

• Benzinga·03/27 13:32

  This Honeywell Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday

• Dow Jones·03/27 12:08

  Genmab Initiated at Outperform by Wolfe Research